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Abstract
Background: Although considered complex and challenging, esophagectomy remains the best potentially curable
treatment option for resectable esophageal and esophagogastric junction (AEG) carcinomas. The optimal surgical
approach and technique as well as the extent of lymphadenectomy, particularly regarding quality of life and short-
and long-term outcomes, are still a matter of debate. To lower perioperative morbidity, we combined the
advantages of a one-cavity approach with extended lymph node dissection (usually achieved by only a two-cavity
approach) and developed a modified single-cavity transhiatal approach for esophagectomy.
Methods: The aim of this study was to evaluate the outcome of an extended transhiatal esophageal resection with
radical bilateral mediastinal en bloc lymphadenectomy (eTHE). A prospective database of 166 patients with
resectable cancers of the esophagus (including adenocarcinomas of the AEG types I and II) were analyzed. Patients
were treated between 2001 and 2017 with eTHE at a tertiary care university center. Relevant patient characteristics
and outcome parameters were collected and analyzed. The primary endpoint was 5-year overall survival. Secondary
outcomes included short-term morbidity, mortality, radicalness of en bloc resection and oncologic efficacy.
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Results: The overall survival rates at 1, 3 and 5 years were 84, 70, and 61.0%, respectively. The in-hospital mortality
rate after eTHE was 1.2%. Complications with a Clavien-Dindo score of III/IV occurred in 31 cases (18.6%). A total of
25 patients (15.1%) had a major pulmonary complication. The median hospital stay was 17 days (interquartile range
(IQR) 12). Most patients (n = 144; 86.7%) received neoadjuvant treatment. The median number of lymph nodes
resected was 25 (IQR 17). The R0 resection rate was 97%.
Conclusion: In patients with esophageal cancer, eTHE without thoracotomy resulted in excellent long-term survival,
an above average number of resected lymph nodes and an acceptable postoperative morbidity and mortality.
Keywords: Esophageal cancer, Extended transhiatal esophagectomy, Long-term survival, En bloc
lymphadenectomy, Short-term outcome
Background
Esophageal cancer is one of the most common malig-
nant tumors of the digestive system and has an unfavor-
able prognosis [1]. In recent decades, careful patient
selection, multimodal treatment concepts, and modified
surgical strategies have led to better outcomes for pa-
tients with locally advanced cancers of the esophagus
and the gastroesophageal junction (GEJ); nevertheless,
further treatment improvements are needed.
Surgery remains the best curative treatment option for
resectable esophageal cancer [2]; however, the optimal
surgical technique is not yet defined and remains the
topic of an ongoing debate with regard to surgical ap-
proaches and techniques (e.g., open vs. minimally inva-
sive vs. robotic and hybrid surgery) and the extent of
lymphadenectomy and its influence on short- and long-
term outcomes.
Minimally invasive esophagectomy approaches (MIE)
and hybrid resections are increasingly used in oncologic
surgery for esophageal carcinoma, showing advantages
regarding postoperative convalescence. However, a real
benefit regarding oncologic safety and long-term survival
is still lacking [3–5].
Two large meta-analyses comparing transhiatal (sin-
gle-cavity approach) and transthoracic (two-cavity ap-
proach) routes have attempted to address the debate
regarding the best surgical approach [6, 7]. Transtho-
racic esophagectomy (Ivor Lewis) is believed to benefit
long-term survival. Due to better tumor exposure and
control, the radicalness of resection and the extent of
lymphadenectomy seem to favor a transthoracic ap-
proach (TTE) as opposed to the transhiatal approach
(THE), which is more focused on decreasing postopera-
tive morbidity (i.e., fewer respiratory complications) and
mortality by preventing formal thoracic access and
avoiding one-lung ventilation [8–10]. However, most
previous studies were retrospective and did not include
neoadjuvant treatment options. Although experienced
groups have developed many different techniques and
approaches, an improvement in the disease-free period
or a significant overall survival benefit of these tech-
niques has not yet been demonstrated.
To combine the advantages of TTE and THE, an
extended transhiatal esophageal resection through a
one-cavity approach including extended transhiatal en
bloc-lymphadenectomy (eTHE) and a cervical esophago-
gastric anastomosis, but not thoracotomy, was intro-
duced. In this descriptive and exploratory retrospective
study, we aimed to evaluate patients who were treated in
a tertiary care center regarding the benefits and potential
limitations of the eTHE technique.
Methods
Patients undergoing a planned esophageal resection be-
tween December 2001 and May 2017 at the Bern Uni-
versity Hospital and University of Bern, Inselspital were
reviewed. All patients were consecutively registered in a
prospective database, which was then evaluated retro-
spectively. Patients 18 to 80 years old with resectable
esophageal cancer (cT1–3, N0–4, and M0) of the intra-
thoracic esophagus or GEJ (Siewert type I and Siewert
type I-II) treated with eTHE and a cervical anastomosis
were eligible for inclusion. Adenocarcinomas, squamous
cell carcinomas, and other carcinomas (e.g., mixed
adeno-neuroendocrine carcinoma) were included. Pa-
tients with benign diseases and those who underwent
partial resections of the distal esophagus (n = 125) and
patients who underwent TTE (n = 9) were excluded. The
independent cantonal ethics committee approved this
study.
Operative approach
eTHE was performed with a small upper midline lapar-
otomy. The lower mediastinal and paraesophageal
dissection was accomplished through opening the dia-
phragmatic hiatus approximately 7 cm anteriorly.
Lymphadenectomy of the celiac trunk (including its
branches) along the pancreas, splenic region and peri-
gastric tissue was performed. Continuing the en bloc
lymphadenectomy towards the mediastinum and neck,
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paraesophageal and mediastinal tissue (including pleura,
pericardial and paraaortic lymph and fatty tissues) and
lymph nodes were removed carefully, avoiding lesions of
the thoracic duct via a “transmediastinal shift tech-
nique”. To achieve this, a long retractor was used to al-
ternatively elevate/rotate the right and left lungs
anteriorly to give free sight and access to the mediasti-
num and thoracic cavity up to the apex/first rib on both
sides (Supp. Figure S2). Rotating the entire mediastinum,
anteriorly alternating the lungs on the right and left
sides provides an open view and access to all mediastinal
structures and paraesophageal tissues, comparable to
that achieved with open thoracotomy (Supp. Figure S3)
[11]. It was, however, of utmost importance to team up
with an experienced anesthesiologist to carefully moni-
tor the blood pressure during this phase of the surgical
procedure and to avoid/treat potential iatrogenic
hypotension. An additional cardio-respiratory status
monitor was placed in the surgeon’s field of view. The
aim was to resect an en bloc specimen of the esophagus
following the anatomical planes to the mediastinum,
comparable to the total mesorectal specimen technique
in advanced colorectal surgery. All tissue between the
pericardium and the aorta, including the pleura laterally
and the tracheal bifurcation, was removed, preferably in
one noninjured piece (Supp. Figure S4). The neck was
opened through a small left cervical incision, similar to
that used for a formal neck dissection, allowing us to
perform a lymphadenectomy of levels 3 to 7 while visu-
alizing and sparing the recurrent laryngeal nerve (RLN)
and the parathyroid glands [12]. A combined dissection
of the remaining short cervical esophagus was performed
from the neck and the abdomen. The gastric conduit
was dissected via a fundus rotation gastroplasty with
successive firings of endoscopic linear staplers on the
distal lesser curvature of the stomach [13]. The gastric
tube was routed through the hiatus into the neck. Then,
a high esophagogastric anastomosis was performed in
the neck, preferably with an end-to-side circular stapler
(25 mm). A nasogastric tube was placed through the
anastomosis under direct vision, and a feeding jejunost-
omy tube was placed at the end of the procedure. Two-
Jackson Pratt drain were placed into both pleura cavities.
Finally, the diaphragm was reconstructed.
Outcomes
A retrospective chart review was performed using a stan-
dardized outcome protocol. Patient demographics,
details regarding the surgical procedure, use of neoadju-
vant chemoradiotherapy (nCRT), tumor-specific vari-
ables and survival outcomes were recorded. A routine
pathology work-up was performed as recommended
[14]. Tumors were classified according to the World
Health Orgnaziation classification [15], and staging was
performed according to the UICC/American Joint Com-
mittee on Cancer (eighth edition) criteria [16].
The primary outcome of this study was 5 year overall
survival. Secondary outcomes included perioperative
morbidity, reoperations, postoperative all-cause mortal-
ity (in-hospital, 30 days, and 90 days) and oncologic
efficacy.
The Clavien-Dindo classification was used for the clas-
sification of perioperative complications [17]. Postopera-
tive complications included anastomotic leakage
(identified clinically or radiographically), respiratory
complications (pneumonia or bronchopneumonia con-
firmed by a computed tomographic scan of the thorax),
cardiovascular complications (defined as persistent
arrhythmia requiring medical treatment and myocardial
infarction), wound infections and other complications
(i.e., recurrent nerve injury). Lack of vocal cord function
recovery within 6 months after surgery was defined as
permanent laryngeal nerve palsy (diagnosed by laryngeal
electromyography). Postoperative mortality was defined
as death from any cause. All patients were regularly eval-
uated at the outpatient department. In the first year,
follow-up consisted of evaluations every 3 months and
every 6 to 12months in the second, third, fourth, and
fifth year postoperatively. Long-term follow-up data
were collected by chart review and, in case of missing
data, by contacting the general practitioner or the pa-
tient directly.
Statistical analysis
The normality of continuous variable distribution was
assessed using histograms, skewness, and the Shapiro–
Wilk test. Categorical variables are reported as numbers
and percentages, and continuous variables are reported
as medians and interquartile ranges (IQRs). Survival was
assessed with Kaplan-Meier curves and life table ana-
lyses. Analyses were performed using SPSS Statistics ver-
sion 24 (IBM, Armonk, NY, USA) and STAT Version 16
(StataCorp, College Station, TX, USA).
Results
Patients characteristics
Between December 2001 and May 2017, 166 patients
were included in the present study. Baseline demograph-
ics and clinical characteristics, including age, sex,
American Society of Anesthesiologists (ASA) classifica-
tion, and comorbidities (e.g., heart disease and pulmon-
ary diseases), are displayed in Table 1. Most patients
were male (78.3%), and cT3 was the most frequently ob-
served clinical tumor stage (63.9%). A total of 144
patients underwent nCRT (86.7%). Radiation was per-
formed with mainly 45 Gy (n = 84) or 50.5 Gy (n = 22).
Chemotherapy was 5-Fluoruracil and Cisplatin/
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Carboplatin based with additional Paclitaxel or Doxe-
taxel. Median follow-up was 29months (IQR 52).
Morbidity and mortality
There were no intraoperative deaths. The in-hospital
mortality rate was 1.2% (n = 2), and the 30- and 90-day
mortality rates were 1.8 and 4.2%, respectively (n = 3).
The postoperative morbidity is summarized in Table 2.
A total of 25 patients (15.1%) had a major pulmonary
complication.
Pathological findings
Adenocarcinoma was the most frequently observed type
of tumor (n = 114; 68.7%). The remaining cases were
squamous cell carcinomas (n = 46; 27.7%) and other can-
cers (n = 6; 3.6%). Carcinomas were mainly located in
the distal esophagus or the GEJ (82.5%). The median
number of resected lymph nodes was 25 (IQR 17). The
R0 resection rate with negative margins on final patho-
logic review was 97% (Table 3). Complete regression of
the primary tumor after neoadjuvant therapy corre-
sponding to tumor regression grade Becker 1a was
observed in 49 of 144 patients (34%) undergoing multi-
modal treatment. Eight patients (16.3%) with complete
regression of the primary tumor had viable lymph node
metastases.
Overall survival
The 1-year survival rate was 84%, the 3-year survival rate
was 70%, and the 5-year survival rate was 61%. The
overall survival curves taking into account all tumor
stages are presented in Fig. 1. Figure 2 shows the
Kaplan-Meier survival curves stratified by pathology
stage. The best 5-year survival was observed in path-
ology stage I patients and in patients with a complete re-
sponse to neoadjuvant treatment (Fig. 3). Supplemental
Fig. S1 shows the Kaplan-Meier survival curves stratified
by tumor type (adenocarcinoma vs. squamous cell
carcinomas).
Discussion
The optimal approach to esophagectomy, regardless of
whether an open or minimally invasive (hybrid/robotic)
technique is used, is challenging and controversial. De-
bates regarding postoperative morbidity and long-term
oncological outcomes are ongoing.
Table 1 Patient characteristics and clinical characteristics
eTHE (n = 166)
Age (years) 67.0 (13.0)
Gender (male/female)a 130/36 (78.3/21.7)
ASA score 2a 53 (31.9)
ASA score 3a 103 (62.0)
ASA score 4a 10 (6.0)
Pulmonary diseasea 49 (29.5)
Cardiovascular diseasea 87 (52.4)
Neoadjuvant treatmenta 144 (86.7)
cT-stage, n (%)
cT1 14 (8.4)
cT2 44 (26.5)
cT3 106 (63.9)
cT4 2 (1.2)
cN-stage, n (%)
cNo 38 (22.9)
cN1 97 (58.4)
cN2 30 (18.1)
cN3 1 (0.6)
Values are medians (interquartile ranges) unless indicated otherwise
eTHE extended transhiatal esophageal resection with radical bilateral
mediastinal en bloc lymphadenectomy, BMI body mass index, ASA American
Society of Anesthesiologists Physical Status Classification System
aValues are numbers (percentages)
Table 2 Operative data and postoperative adverse outcomes
after eTHE
eTHE (n = 166)
Operating time (min) 380 (88)
Blood loss (ml) 500 (238)
Clavien-Dindoa
I 32 (19.3)
II 60 (36.1)
III 19 (11.4)
IV 12 (7.2)
V 3 (1.8)
Vocal cord paresis/paralysisa
Transient 18 (10.8)
Permanent 1 (0.6)
Anastomotic leaka 19 (11.4)
Reoperation overalla 9 (5.4)
Revision for leakagea 3 (1.8)
SSIa 16 (9.6)
Cardiovascular complicationsa 51 (30.7)
Hospital-acquired pneumoniaa 21 (12.7)
ARDSa 4 (2.4)
In-hospital mortalitya 2 (1.2)
30-day mortalitya 3 (1.8)
90-day mortalitya 7 (4.2)
Total hospital LOS 17 (12.0)
Values are medians (interquartile ranges) unless indicated otherwise
eTHE extended transhiatal esophageal resection with radical bilateral
mediastinal en bloc lymphadenectomy, ARDS acute respiratory distress
syndrome, SSI surgical site infection, LOS length of stay
a Values are numbers (percentages)
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This single-institution review of the open eTHE tech-
nique for esophageal cancer demonstrates the low peri-
operative morbidity and mortality of this approach with
above-average overall long-term survival.
The transhiatal technique was introduced in the 1970s
by Orringer et al., and its efficacy was demonstrated
shortly after its introduction [18]. The advantage of the
transhiatal technique is the avoidance of a two-cavity ap-
proach, omitting thoracotomy. The aim was a) to reduce
surgical trauma and minimize pulmonary complications,
b) to establish a cervical esophageal anastomosis in a
position where a postoperative leak can be treated easily,
and c) to avoid a mediastinal anastomosis with the risk
of mediastinitis and sepsis.
Anastomotic leaks occur in 9–14% of cases, and some
small studies have reported an incidence as low as 1.8%
[18, 19]. In our study, the leak rate was 11.4%, with 1.8%
of cases requiring surgery and drainage, and the inci-
dence of temporary RLN injury was 10.8%. One patient
suffered from permanent RLN (0.6%), which is compar-
able to the frequency reported in a meta-analysis of
more than 5000 patients [6]. The pulmonary complica-
tion rate was acceptable (12.4%) and comparable to re-
sults from the Esophagectomy Complications Consensus
Group with pneumonia rates of 11.4% [20].
The overall postoperative 30-day mortality rate was
1.8%, which was similar to that in other MIE studies
[21]. The 90-day mortality rate was 4.2%, which was less
than half of the rate reported in the National Cancer
Database (8.9%) [22].
The conclusion of a subsequent analysis in the HIVEX
trial [23] was that TTE was the preferred technique,
whereas THE should be considered only in patients with
a carcinoma located at the GEJ or in patients with a
poor performance status. This conclusion could not be
confirmed in the present study. The baseline characteris-
tics of patients in our cohort (e.g., patient population
age, gender, comorbidities, neoadjuvant therapy, tumor
histology, site, and stage) are comparable to those of
other single-center esophagectomy research groups at
major academic medical centers and multi-institution
studies of esophagectomy [10, 24, 25]. Although the
ASA classification might be a subjective parameter, the
number of patients with ASA III and ASA IV was sig-
nificantly higher in our cohort than in other studies [26].
Most importantly, with eTHE, the factors regarding
oncologic efficacy, such as lymph node harvest, complete
resection rate (R0 of 97%), and long-term survival out-
comes, were no compromised compared to those of
other open or laparoscopic approaches. A recent study
comparing open TTE to minimally invasive TTE showed
no significant difference in long-term survival for up to
3 years (40.2% (±6.9) vs. 35.9% (±6.8%)) [25]. Our long-
term outcomes are superior with overall survival rates at
3 and 5 years of 70 and 61%, respectively [9, 25–27].
There are probably various reasons for this discrepancy,
which will be discussed in the following section.
The oncologic appropriateness of the THE has been
questioned because critics argue that a thoracic medias-
tinal lympadenectomy cannot be performed adequately
with the transhiatal approach. A population-based co-
hort study in the Netherlands demonstrated a survival
advantage was achieved with an increasing number of
removed lymph nodes (HR 0.84; 0.78–0.90 per 10 more
lymph nodes removed). In the transthoracic resection
approach, a median of 19 (range 14–25) lymph nodes
Table 3 Histological features after eTHE
eTHE (n = 166)
Tumor localization, n (%)
Upper third 1 (0.6)
Middle third 28 (16.9)
Distal third 137 (82.5)
AEG Typ I 101 (73.7)
AEG Typ II 29 (21.2)
Tumor entity, n (%)
Squamous carcinoma, n (%) 46 (27.7)
Adenocarcinoma, n (%) 114 (68.7)
Others 6 (3.6)
(y) pT-Stagea
ypT0 42 (25.3)
(y) pT1 46 (27.7)
(y)pT2 22 (13.3)
(y)pT3 56 (33.7)
N-Stagea
pN0 111 (66.9)
pN1 32 (19.3)
pN2 16 (9.6)
pN3 7 (4.2)
TNM 8-Stagea
I 89 (53.6)
II 19 (11.4)
IIIA 15 (9.0)
IIIB 30 (18.1)
IVA 7 (4.2)
IVB 6 (3.6)
RO resection 161 (97.0)
No. of resected lymph nodes 25 (17.0)
Complete response (Becker 1a)a 49 (34.0)
Values are medians (interquartile ranges) unless indicated otherwise
eTHE extended transhiatal esophageal resection with radical bilateral
mediastinal en bloc lymphadenectomy
a Values are numbers (percentages)
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was removed, whereas considerably fewer lymph nodes
were removed during transhiatal resection (median 12,
range 8–17). The median overall number of lymph
nodes resected in our study cohort, including patients
who underwent nCRT (86.7%), was 25, which is higher
than the average number reported [27] and disproves
the statement that a transhiatal approach allows lymph
node dissection to only a limited extent. Peyre et al. even
suggested that the optimal threshold for this survival
benefit was the removal of at least 23 nodes, and the
surgical procedure to achieve this number with a high
likelihood was en bloc resection [28].
By opening the diaphragm anteriorly and thus having
full visibility of all essential structures in the
Fig. 1 Kaplan-Meier plots of the estimated overall survival for up to 5 years after cancer resection
Fig. 2 Five-year survival stratified by pathological tumor stage. UICC, Union for International Cancer Control
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mediastinum, the advantages of TTE (radicalness) and
THE (low morbidity, one-cavity approach and no need
for one-lung ventilation) were combined by the eTHE.
A complete en bloc total mesorectal excision, the
emerged standard of care in colorectal surgery, has been
defined as the “complete removal of the lymph node-
bearing mesorectum along with its intact enveloping
fascia” [29]. The same authors have also shown that an
incomplete total mesorectal excision is associated with
an increased risk of recurrence and a decreased overall
survival [30]. Preparation along embryonic layers of the
upper gastrointestinal tract is also attracting increasing
attention among oncologists, although its scientific basis
and superiority have not yet been proven. Following the
principles of total mesorectal resection, Cuesta et al. de-
scribed the “meso-esophagus” for the first time [31].
This principle of respecting the planes surrounding the
specimen being transferred to esophageal cancer surgery
might be crucial and may have contributed to the excel-
lent long-term results in our eTHE series with en bloc
resection and high numbers of resected lymph nodes.
The use of long laparoscopic instruments was precious
and enabled a save and radical dissection and resection
in the mid and upper mediastinum along with the land-
marks also for tumors in the middle third of the esopha-
gus. However, there are certain limitations for tumours
(bulky tumours, metastatic lymph nodes) in the middle
third for the eTHE technique, and a classic open IVOR
Lewis approach is also a good option. However, the
number of carcinomas in the upper third (n = 1, 0.6%) of
the esophagus was low in our study. High cervical
esophagus carcinoma, non-responding to radiochemo-
therapy were sporadic and could be treated with total
laryngo-esophagectomy, but no patient underwent such
a procedure during the period. We usually performed a
2-field lymphadenectomy up to the level of the vena azy-
gos, but in single cases, lymphadenectomy of the
supraaortal lymph nodes via deep cervical access is also
possible.
The eTHE technique in our study was pursued in
order to reduce the pulmonary complication rate of an
open transthoracic esophageal resection by avoiding
thoracotomy and single lung ventilation. Open transtho-
racic esophagectomy is burdened by a postoperative
pneumonia rate of 12–55% even in recent randomized
trials [25, 32, 33]. Besides the surgical trauma of the re-
section itself, the surgical access trauma seems crucial
for the pulmonary function, as all randomized trials
comparing open and minimally invasive esophagectomy
display a substantial reduction of the pulmonary compli-
cation rate in the minimally invasive cohort. Very inter-
estingly, this holds for all types of minimally invasive
access, i.e., a combination of intrathoracic of cervical
anastomoses like in the TIME trial [25], fully robotic ac-
cess like in the Dutch ROBOT trial published by van der
Sluis et al. [32], and even for the hybrid access as pub-
lished by French FREGAT group in the MIRO trial [33].
Comparing the results of our study to the outcome of
the MIRO trial, short-term results were comparable
about rates of major postoperative complications accord-
ing to Clavien-Dindo classification. In our series, postop-
erative pneumonia and ARDS rate was 12.7 and 2.4%,
Fig. 3 Five-year survival stratified by Becker regression grade
Kröll et al. BMC Surgery          (2020) 20:197 Page 7 of 10
respectively, as compared to 12.8 and 7.8%, respectively,
in the hybrid-procedure group of the MIRO trial [33].
Both results compare at least similar to the 28% pneu-
monia rate of the ROBOT trial [32] and the 12% pneu-
monia rate of the TIME trial [25]. Therefore, the
inherent pulmonary complication rate of an esophageal
resection seems to be significantly aggravated by the de-
struction of the primary and auxiliary respiratory muscu-
lature at the chest and abdominal level through an open
two-cavity Ivor-Lewis resection. Even avoiding one of
these resections by using either a minimally invasive ap-
proach or – in our case – a transhiatal access, prevents
the body from the “double hit” of the open esophagec-
tomy and reduces postoperative pulmonary failure.
Our data, together with the studies mentioned above,
seem to indicate that in the setting of esophagectomy,
firstly, it seems irrelevant which side of the diaphragm
remains without a long incision. Secondly, the surgical
trauma and postoperative morbidity of the removal of
the esophagus itself seems to transfer a “baseline” mor-
bidity, which overlays the presumed additional benefit of
a total minimally invasive procedure, resulting in favor-
able postoperative complication rates in both our and
the MIRO hybrid cohort compared to the Dutch
ROBOT and the TIME total minimally invasive patient
cohort. In conclusion, the presented modified eTHE
technique resulted in limited surgical trauma avoiding
thoracotomy with consecutive pulmonary morbidity and
without jeopardizing the radicality of the procedure
since extensive lymphadenectomy was still feasible.
In the current era of MIE, the advantage of an open
eTHE with a small supraumbilical incision may become
more significant if long-term oncological outcomes of
MIE are similar to those of open techniques. Further-
more, robotic and mediastinoscope assisted-transhiatal
esophagectomy has found its place among minimally in-
vasive techniques and is becoming more popular [34,
35]. Mori et al. developed a new robotic technique,
“nontransthoracic esophagectomy”, with promising re-
sults. The authors described the performance of an im-
proved transhiatal nodal dissection without the
disadvantages of a thoracic approach. While this tech-
nique potentially represents an interesting alternative to
current surgical procedures, it needs to be further evalu-
ated, even for advanced stages of cancer.
Beyond the selection of the surgical technique, the im-
plementation of multimodal therapy, the extent of surgi-
cal resection, the experience of the surgeon, and the
operative volume as well as improvements in critical
care management in the hospital may also play import-
ant roles in both short-term and long-term efficacy and
outcomes [18, 36, 37].
The limitations of this study are those commonly asso-
ciated with retrospective studies. There following
confounding factors were present: differences in patient
characteristics, increasing surgical experience, expertise
in postoperative management and critical care and evo-
lution over this long study period. Other limitations of
the present study are the relatively small number of pa-
tients analyzed and the single-center approach.
Conclusions
In conclusion, this single-center cohort study demon-
strates that extended transhiatal esophageal resection
without thoracotomy is associated with low peri- and
postoperative morbidity and mortality. With eTHE, rad-
ical resection including extensive mediastinal lymphade-
nectomy is feasible, and this oncologically sound
procedure resulted in above-average long-term survival
rates compared to those achieved with other techniques
described in the literature.
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